|
IMMUNODEFICIENCY 42
|
0.600 |
GermlineCausalMutation
|
disease |
ORPHANET |
IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.
|
26160376 |
2015 |
|
IMMUNODEFICIENCY 42
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.
|
26160376 |
2015 |
|
IMMUNODEFICIENCY 42
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.
|
26160376 |
2015 |
|
IMMUNODEFICIENCY 42
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Delayed Sleep Phase Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circadian polymorphisms in night owls, in bipolars, and in non-24-hour sleep cycles.
|
25395965 |
2014 |
|
Nonorganic Sleep Wake Cycle Disorders
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circadian polymorphisms in night owls, in bipolars, and in non-24-hour sleep cycles.
|
25395965 |
2014 |
|
Advanced Sleep Phase Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circadian polymorphisms in night owls, in bipolars, and in non-24-hour sleep cycles.
|
25395965 |
2014 |
|
Non-24 Hour Sleep-Wake Disorder
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circadian polymorphisms in night owls, in bipolars, and in non-24-hour sleep cycles.
|
25395965 |
2014 |
|
Shift-Work Sleep Disorder
|
0.300 |
Biomarker
|
disease |
CTD_human |
Circadian polymorphisms in night owls, in bipolars, and in non-24-hour sleep cycles.
|
25395965 |
2014 |
|
Sleep Disorders, Circadian Rhythm
|
0.300 |
Biomarker
|
group |
CTD_human |
Circadian polymorphisms in night owls, in bipolars, and in non-24-hour sleep cycles.
|
25395965 |
2014 |
|
Inflammation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression of NLRP3, CASPASE-1, CD3ɛ (pan T cells), TBX21 (T(h)1 cells) and RORC (T(h)17 cells) was positively, whereas GATA3 (T(h)2 cells) was inversely correlated with AT inflammation.
|
22325453 |
2012 |
|
Sicca Syndrome
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Sjogren's Syndrome
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Congenital hypoplasia of thymus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
TOR conservation from flies to humans indicates that probiotic therapy with L. fermentum NCIMB 5221 has a high therapeutic potential towards several human energy regulatory diseases such as obesity, diabetes and cancer.
|
30368647 |
2019 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, the mechanistically investigation showed DT-13 activated AMPK and inhibited m-TOR to block cancer growth in vitro.
|
30668361 |
2019 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Lower dose of TOR-I compared with higher doses probably makes little or no difference to death (RR 0.84, 95% CI 0.67 to 1.06; 13 studies), graft loss censored for death (RR 0.92, 95% CI 0.71 to 1.19; 12 studies), biopsy-proven acute rejection (RR 1.26, 95% CI 1.10 to 1.43; 11 studies), CMV infection (RR 0.87, 95% CI 0.63 to 1.21; 9 studies), wound complications (RR 0.92, 95% CI 0.66 to 1.29; 7 studies), and malignancy (RR 0.84, 95% CI 0.54 to 1.32; 10 studies) (moderate certainty evidence); and may make little or no difference to the need to change treatments (RR 0.91, 95% CI 0.78 to 1.05; 10 studies) (low certainty evidence).
|
31840244 |
2019 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Two structurally and functionally distinct mammalian TOR complexes control cell growth and metabolism in physiological and pathological contexts including cancer.
|
28303961 |
2017 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
m-TOR inhibitors and their potential role in haematological malignancies.
|
28146265 |
2017 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
TOR is a master regulator of the cell's growth and metabolic state, and its dysregulation contributes to a variety of diseases, including diabetes, obesity, neurodegenerative disorders, aging, and cancer, making the TOR pathway an attractive therapeutic target.
|
28888322 |
2017 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In this regard, the GHRH-GH-IGF-1/Insulin, TOR-S6K1,NAD(+)-Sirtuin, P53, Klotho and APOE pathways have been linked to processes associated with age-related diseases, including cancer, cardiovascular disease, diabetes, osteoporosis, and neurodegenerative diseases, all of which directly influence health in aging, and represent key targets in anti-aging therapy.
|
25038521 |
2014 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Cancer and aging share a lot in common including the activation of the TOR pathway.
|
22246147 |
2011 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Lower dose of TOR-I compared with higher doses probably makes little or no difference to death (RR 0.84, 95% CI 0.67 to 1.06; 13 studies), graft loss censored for death (RR 0.92, 95% CI 0.71 to 1.19; 12 studies), biopsy-proven acute rejection (RR 1.26, 95% CI 1.10 to 1.43; 11 studies), CMV infection (RR 0.87, 95% CI 0.63 to 1.21; 9 studies), wound complications (RR 0.92, 95% CI 0.66 to 1.29; 7 studies), and malignancy (RR 0.84, 95% CI 0.54 to 1.32; 10 studies) (moderate certainty evidence); and may make little or no difference to the need to change treatments (RR 0.91, 95% CI 0.78 to 1.05; 10 studies) (low certainty evidence).
|
31840244 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
TOR conservation from flies to humans indicates that probiotic therapy with L. fermentum NCIMB 5221 has a high therapeutic potential towards several human energy regulatory diseases such as obesity, diabetes and cancer.
|
30368647 |
2019 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Furthermore, the mechanistically investigation showed DT-13 activated AMPK and inhibited m-TOR to block cancer growth in vitro.
|
30668361 |
2019 |